• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    9/25/23 4:17:04 PM ET
    $SBTX
    Specialty Chemicals
    Consumer Discretionary
    Get the next $SBTX alert in real time by email
    8-K
    false 0001671858 0001671858 2023-09-25 2023-09-25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    September 25, 2023

    Date of Report (Date of earliest event reported)

     

     

    ARS Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39756   81-1489190

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    11682 El Camino Real, Suite 120

    San Diego, California

      92130
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (858) 771-9307

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   SPRY   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01.

    Regulation FD Disclosure.

    On September 25, 2023, ARS Pharmaceuticals, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company’s website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

    The information under this Item 7.01 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    99.1    Company Presentation
    104    Cover Page of Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 25, 2023     ARS Pharmaceuticals, Inc.

     

        By:  

    /s/ Richard Lowenthal, M.S., MSEL

     

        Name:   Richard Lowenthal, M.S., MSEL

     

        Title:   President and Chief Executive Officer
    Get the next $SBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBTX

    DatePrice TargetRatingAnalyst
    4/4/2022$25.00 → $3.50Buy → Neutral
    Goldman
    4/1/2022$25.00 → $1.80Outperform → Mkt Perform
    SVB Leerink
    4/1/2022$32.00 → $6.00Buy → Hold
    Stifel
    4/1/2022Buy → Neutral
    H.C. Wainwright
    11/12/2021$42.00 → $25.00Outperform
    SVB Leerink
    8/16/2021$46.00 → $49.00Outperform
    SVB Leerink
    More analyst ratings

    $SBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silverback Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously

      4/4/22 7:33:52 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously

      4/1/22 9:04:51 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously

      4/1/22 7:22:09 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:53:49 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Karas Eric

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:47:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:45:07 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

      Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle

      11/10/22 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

      Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus

      11/8/22 4:02:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

      neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U

      10/21/22 7:31:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/9/24 8:35:56 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/25/23 4:30:47 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/1/23 4:15:58 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      10/2/23 4:23:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/25/23 4:30:22 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Financials

    Live finance-specific insights

    See more

    $SBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

      Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap

      7/21/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

      - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron

      3/31/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

      – Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu

      9/16/21 3:30:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

      SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve

      3/15/21 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Silverback Therapeutics Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:04:53 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:02:29 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      9/25/23 4:17:04 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary